Multiple Myeloma: Our Clinical Trials

Here you can find a continually updated listing of Memorial Sloan Kettering’s current clinical trials for multiple myeloma and related plasma cell diseases.

Showing 28 trials
Titlesort icon Investigator
A Study Comparing Different Stem Cell Mobilization Approaches in Patients with Multiple Myeloma
[Protocol 13-176]
Landau, Heather, MD
A Pilot Study of the Wilms' Tumor 1 (WT1) Analog Peptide Vaccine in Patients with Multiple Myeloma after Autologous Stem Cell Transplantation
[Protocol 12-288]
Koehne, Guenther, MD, PhD
A Pilot Study of Bortezomib/Dexamethasone Followed by Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone for the Initial Treatment of MIDD Associated with Multiple Myeloma and Amyloidosis
Newly Diagnosed
[Protocol 11-061]
Hassoun, Hani, MD
A Pilot Study of Acupuncture to Control Symptoms in Patients Receiving Stem Cell Transplantation for Multiple Myeloma
[Protocol 13-038]
Deng, Gary, MD, PhD
A Phase III Study of Lenalidomide, Bortezomib, and Dexamethasone Combination Treatment with or without Peripheral Stem Cell Transplantation in the Initial Management of Multiple Myeloma
Newly Diagnosed
[Protocol 12-018]
Hassoun, Hani, MD
A Phase II Trial of Transplants from HLA-Compatible Donors with T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System for the Treatment of Patients with Hematologic Malignancies and Disorders
[Protocol 10-050]
O'Reilly, Richard, MD
A Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers
[Protocol 12-131]
Hyman, David, MD
A Phase II Study of Pomalidomide plus Autologous Stem Cell Transplantation versus Pomalidomide/Dexamethasone in Patients with Multiple Myeloma
Relapsed/Refractory
[Protocol 12-138]
Giralt, Sergio, MD
A Phase II Study of PCI-32765 in Patients with Relapsed and/or Refractory Multiple Myeloma
Relapsed/Refractory
[Protocol 12-055]
Lendvai, Nikoletta, MD
A Phase II Study of Lenalidomide Intensification in Patients with Asymptomatic Multiple Myeloma that Has Progressed with Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation
Newly Diagnosed
[Protocol 11-107]
Hassoun, Hani, MD
A Phase II Study of Lenalidomide and Low-Dose Dexamethasone (LD) Followed by Continued LD or Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma
[Protocol 08-121]
Hassoun, Hani, MD
A Phase II Study of Carfilzomib with or without ARRY-520 in Patients with Advanced Multiple Myeloma
[Protocol 13-241]
Lendvai, Nikoletta, MD
A Phase II Study of Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post-Transplantation Donor Lymphocyte Infusions for Patients with Relapsed or High-Risk Multiple Myeloma
[Protocol 10-051]
Koehne, Guenther, MD, PhD
A Phase II Study of Bulk Versus Fractionated Stem Cell Infusions in Patients with Hematologic Cancers Undergoing Stem Cell Transplantation
[Protocol 12-016]
Giralt, Sergio, MD
A Phase II Study of Bortezomib/Dexamethasone Followed by Lenalidomide in Nonresponders as Initial Treatment for Multiple Myeloma
[Protocol 13-064]
Hassoun, Hani, MD
A Phase IB/IIA Study of Romidepsin plus Lenalidomide in Adults with Relapsed or Refractory Lymphoma and Myeloma
Relapsed/Refractory
[Protocol 12-170]
Horwitz, Steven, MD
A Phase IB/IIA Study of ABT-888 in Combination with Bendamustine with or without Rituximab in Patients with Lymphoma, Multiple Myeloma, and Solid Tumors
[Protocol 10-174]
Gerecitano, John, MD, PhD
A Phase IB Study of SAR650984 with Lenalidomide and Dexamethasone to Treat Recurrent or Persistent Multiple Myeloma
[Protocol 13-006]
Lendvai, Nikoletta, MD
A Phase I/IIA Study of Carfilzomib plus High-Dose Melphalan Before Autologous Stem Cell Transplant in Patients with Multiple Myeloma
[Protocol 12-144]
Landau, Heather, MD
A Phase I/II Study of Pomalidomide and Dexamethasone with and without Ixazomib in Patients with Recurrent Multiple Myeloma
[Protocol 14-055]
Hassoun, Hani, MD
A Phase I/II Study of GSK525762 in Patients with Persistent Hematologic Cancers
[Protocol 13-202]
Stein, Eytan, MD
A Phase I/II Study of Cabozantinib (XL184) in Patients with Recurrent or Persistent Myeloma
Relapsed/Refractory
[Protocol 12-240]
Giralt, Sergio, MD
A Phase I Study of WT1-Specific Donor-Derived T Cells in Patients with Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia after T-Cell-Depleted Allogeneic Stem Cell Transplantation
Relapsed/Refractory
[Protocol 12-175]
Koehne, Guenther, MD, PhD
A Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Hematologic Cancers
Relapsed/Refractory
[Protocol 12-142]
Lesokhin, Alexander, MD
A Phase I Study of GSK2857916 in Patients with Recurrent or Persistent Multiple Myeloma
[Protocol 14-105]
Lendvai, Nikoletta, MD
A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Relapsed/Refractory
[Protocol 13-045]
Younes, Anas, MD
A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
[Protocol 14-053]
Younes, Anas, MD
A Phase I Study of an mRNA-Modified Dendritic Cell Vaccine in Patients with Multiple Myeloma as Consolidation Treatment after Autologous Stem Cell Transplantation
[Protocol 13-009]
Chung, David, MD, PhD